Targacept to Report Fourth Quarter and 2012 Financial Results on February 13, 2013

  Targacept to Report Fourth Quarter and 2012 Financial Results on February
  13, 2013

Business Wire

WINSTON-SALEM, N.C. -- February 6, 2013

Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company
developing novel NNR Therapeutics™, today announced that it will report
financial results for the fourth quarter and year ended December 31, 2012 on
Wednesday, February 13, 2013, after the U.S. financial markets close.

Management will discuss the fourth quarter and year-end financial results,
provide a business and program update and discuss expectations for the future
via conference call at 5:00 p.m. Eastern Time on Wednesday, February 13, 2013.
The conference call may be accessed by dialing 800.322.2803 for domestic
participants and 617.614.4925 for international callers (reference passcode
41520275). A replay of the conference call may be accessed from approximately
8:00 p.m. Eastern Time on February 13, 2013 through February 27, 2013 by
dialing 888.286.8010 for domestic callers and 617.801.6888 for international
callers (reference passcode 46454957).

A live audio webcast of the conference call will be accessible from the
Investor Relations page of Targacept’s website, www.targacept.com. To ensure a
timely connection to the webcast, it is recommended that users register at
least 15 minutes prior to the scheduled start time. An archived version of the
webcast will also be available for replay on the Investor Calendar section of
the Investor Relations page of Targacept’s website for at least two weeks
following the call.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics(TM)
for difficult-to-treat diseases and disorders of the nervous system. NNR
Therapeutics selectively modulate the activity of specific neuronal nicotinic
receptors, unique proteins that regulate vital biological functions that are
impaired in various disease states. Targacept’s clinical pipeline includes
multiple Phase 2 product candidates, all representing first-in-class
opportunities. Targacept leverages its scientific leadership diverse pipeline
to attract significant collaborations with global pharmaceutical companies.
For more information, please visit www.targacept.com.


Building Health, Restoring Independence®


Targacept, Inc.
Alan Musso, 336-480-2186
SVP, Finance and Administration and CFO
Linnden Communications
Michelle Linn, 508-362-3087
Press spacebar to pause and continue. Press esc to stop.